Skip to Main Content

Paper Details

The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
Clin Cancer Res
4
2023
AKT, AMG 479, FN, FN RMS, IGF1R, MAP kinase, MEK, MEK1/2, PAX, PAX-fusion, PAX-fusion negative rhabdomyosarcoma, PI3K, PTEN, RAS, RAS-mutant FN RMS, RAS-mutant FN RMS cell lines, RAS-mutated FN RMS preclinical models, RAS-mutated PAX-fusion negative rhabdomyosarcoma models, RAS-mutated cell-line, RMS, SCID, cell line, cell lines, ganitumab, human, human and murine IGF1R, mice, murine, mutant, mutant RMS, patient, patient derived xenograft models, rhabdomyosarcoma, trametinib, tumor
Author NameAffiliation
David J LiewehrCenter for Cancer Research
David J LiewehrCenter for Cancer Research
Jack F ShernCenter for Cancer Research
Frederic G BarrCenter for Cancer Research
Frederic G BarrCenter for Cancer Research
Javed KhanCenter for Cancer Research
Javed KhanCenter for Cancer Research
  • 1 - 7

Datasets

Release 1.2